TALEN

TALEN2-sphk2

ID
ZDB-TALEN-151201-1
Name
TALEN2-sphk2
Previous Names
None
Target
Target Sequence 1
5' - GCAAAAGCATGTTGCCTCGT - 3'
Target Sequence 2
5' - GAATGGATTGACCAGCAG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genome Build: GRCz11Chromosome: 16
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
wcm2 sphk2
Expression
Gene expression in Wild Types + TALEN2-sphk2
No data available
Phenotype
Phenotype resulting from TALEN2-sphk2
No data available
Phenotype of all Fish created by or utilizing TALEN2-sphk2
Phenotype Fish Conditions Figures
gastrulation delayed, abnormal sphk2wcm2/wcm2 control Fig. 2 with image from Mendelson et al., 2017
cell migration to the midline involved in heart development decreased occurrence, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with imageFig. 4 with image from Mendelson et al., 2015
oocyte cers2b expression increased amount, abnormal sphk2wcm2/wcm2 standard conditions Fig. 7 with image from Mendelson et al., 2017
post-vent region epithelium blistered, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with image from Mendelson et al., 2015
yolk syncytial layer increased width, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 3 with image from Mendelson et al., 2017
post-vent region epithelium blistered, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with image from Mendelson et al., 2015
EVL epiboly delayed, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 3 with image from Mendelson et al., 2017
whole organism sphingosine increased amount, abnormal sphk2wcm2/wcm2 standard conditions Fig. 1 with image from Mendelson et al., 2017
actin filament organization disrupted, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 3 with image from Mendelson et al., 2017
yolk syncytial layer increased width, abnormal sphk2wcm2/wcm2 chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 3 with image from Mendelson et al., 2017
epiboly delayed, abnormal sphk2wcm2/wcm2 standard conditions Fig. 1 with imageFig. 2 with image from Mendelson et al., 2017
epiboly delayed, abnormal sphk2wcm2/wcm2 chemical treatment by environment: 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol Fig. 3 with image from Mendelson et al., 2017
EVL epiboly delayed, abnormal sphk2wcm2/wcm2 chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 3 with image from Mendelson et al., 2017
heart edematous, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with image from Mendelson et al., 2015
whole organism cers2b expression increased amount, abnormal sphk2wcm2/wcm2 standard conditions Fig. 4 with image from Mendelson et al., 2017
epiboly delayed, abnormal sphk2wcm2/wcm2 chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 3 with image from Mendelson et al., 2017
yolk actin cytoskeleton organization disrupted, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 3 with image from Mendelson et al., 2017
actin filament organization disrupted, abnormal sphk2wcm2/wcm2 chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 3 with image from Mendelson et al., 2017
gastrulation delayed, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 2 with image from Mendelson et al., 2017
heart tube split bilaterally, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with image from Mendelson et al., 2015
heart tube increased amount, abnormal sphk2wcm2/wcm2 control Fig. 2 with image from Mendelson et al., 2017
heart tube split bilaterally, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with imageFig. 4 with image from Mendelson et al., 2015
embryonic heart tube formation decreased occurrence, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with imageFig. 4 with image from Mendelson et al., 2015
oocyte sphingoid 1-phosphate absent, abnormal sphk2wcm2/wcm2 standard conditions Fig. 7 with image from Mendelson et al., 2017
embryonic heart tube formation decreased occurrence, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with image from Mendelson et al., 2015
yolk actin cytoskeleton organization disrupted, abnormal sphk2wcm2/wcm2 chemical treatment by environment: 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol Fig. 3 with image from Mendelson et al., 2017
EVL junctional membrane complex morphology, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 3 with image from Mendelson et al., 2017
yolk actin cytoskeleton organization disrupted, abnormal sphk2wcm2/wcm2 chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 3 with image from Mendelson et al., 2017
yolk syncytial layer microtubule cytoskeleton increased length, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 3 with image from Mendelson et al., 2017
actin filament organization disrupted, abnormal sphk2wcm2/wcm2 chemical treatment by environment: 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol Fig. 3 with image from Mendelson et al., 2017
yolk syncytial layer microtubule cytoskeleton increased length, abnormal sphk2wcm2/wcm2 chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 3 with image from Mendelson et al., 2017
oocyte sphingosine increased amount, abnormal sphk2wcm2/wcm2 standard conditions Fig. 7 with image from Mendelson et al., 2017
EVL epiboly delayed, abnormal sphk2wcm2/wcm2 chemical treatment by environment: 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol Fig. 3 with image from Mendelson et al., 2017
heart tube increased amount, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 2 with image from Mendelson et al., 2017
whole organism sphingosine 1-phosphate decreased amount, abnormal sphk2wcm2/wcm2 standard conditions Fig. 1 with image from Mendelson et al., 2017
epiboly delayed, abnormal sphk2wcm2/wcm2 chemical treatment by environment: sphingosine Fig. 2 with imageFig. 3 with image from Mendelson et al., 2017
EVL junctional membrane complex morphology, abnormal sphk2wcm2/wcm2 chemical treatment by environment: EC 2.7.1.91 (sphingosine kinase) inhibitor Fig. 3 with image from Mendelson et al., 2017
cell migration to the midline involved in heart development decreased occurrence, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with image from Mendelson et al., 2015
heart edematous, abnormal sphk2wcm2/wcm2 standard conditions Fig. 3 with image from Mendelson et al., 2015
whole organism asah1a expression increased amount, abnormal sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism asah2 expression decreased amount, abnormal sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
margin decreased diameter, abnormal sphk2wcm2/wcm2 + MO1-cers2b standard conditions Fig. 4 with image from Mendelson et al., 2017
gastrulation delayed, abnormal sphk2wcm2/wcm2 + MO1-cers2b standard conditions Fig. 4 with image from Mendelson et al., 2017
yolk hourglass-shaped, abnormal sphk2wcm2/wcm2 + MO1-cers2b standard conditions Fig. 4 with image from Mendelson et al., 2017
whole organism necrotic, abnormal cers2bwcm18/wcm18; sphk2wcm2/wcm2 standard conditions Fig. 4 with image from Mendelson et al., 2017
whole organism dead, abnormal cers2bwcm18/wcm18; sphk2wcm2/wcm2 standard conditions Fig. 4 with image from Mendelson et al., 2017
whole organism dnajc3a expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
liver increased size, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism gpx1a expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism il1b expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
hepatocyte increased size, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
liver lipid increased amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism txnl1 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism col1a1a expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism xbp1 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism atf4a expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism asah1a expression increased amount, abnormal kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism txnl4a expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism edem1 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism asah1b expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism nfe2l2a expression increased amount, abnormal kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism gpx4a expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism prdx4 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism serpina1 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism ern1 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism sgpl1 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism atf6 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism tnfa expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism sphk2 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism bcl2l11 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism hspa5 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism sgpp1b expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism ddit3 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism sod2 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism asah2 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 5 with image from Park et al., 2019
whole organism bida expression increased amount, abnormal kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism hsp90b1 expression increased amount, abnormal kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism nfkb1 expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism gadd45aa expression increased amount, abnormal kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
whole organism baxb expression amount, ameliorated kdsrmuz106/muz106; sphk2wcm2/wcm2 (AB/TU) standard conditions Fig. 6 from Park et al., 2019
Citations